Srivani Ravoori, PhD

Srivani Ravoori, PhD, is associate director of science communications at the AACR. Ravoori is an experienced science content developer and an expert in translating complex cancer science into simple language with the goal of educating the public, media, policymakers, and the health care industry about the importance of cancer research. She guides the Communications and Public Relations department in identifying the latest cancer research advances and disseminate them through various print and social media platforms. She holds a PhD degree in cancer biology and dedicated the first 15 years of her career to conducting basic and translational cancer research.

Do Genomic Approaches to Selecting Cancer Treatment Yield Better Patient Outcomes Than Traditional Approaches?

A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput genomic analysis in identifying targeted therapies and delivering better outcomes for cancer patients, and adds important evidence to argue in favor of such an approach. The jury, nevertheless, is still out.

Read More

AACR Annual Meeting 2017: Challenging the Dogma of Treating IDH-mutant Cancers With IDH Inhibitors

Two studies presented at the AACR Annual Meeting 2017 showed that tumors that have mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to that of BRCA-mutant tumors and are, therefore, more likely to respond better to PARP inhibitors than to IDH inhibitors.

Read More

AACR Annual Meeting 2017: If You Can’t Drug It, Degrade It – A Protein Degradation Technology to Tackle Undruggable Oncoproteins

Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers in the field of oncology drug development.

Read More

AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types

Now that a plethora of clinical trials have established positive responses from immunotherapies—immune checkpoint inhibitors, in particular—in patients with a variety of cancer types, one of the logical next questions is, are the responses durable?

Read More